Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib Maintenance vs Consolidation in MCL
NCT00310037Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jun 2006
- Primary completion
- Dec 2013
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib in mantle cell lymphoma (MCL) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Progression-free Survival Rate at 18 months. Started Jun 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00310037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00310037.